No Data
No Data
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $52
LifeSci Capital analyst Sam Slutsky maintains $Immunovant(IMVT.US)$ with a buy rating, and maintains the target price at $52.According to TipRanks data, the analyst has a success rate of 47.4% and a t
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Immunovant Is Maintained at Outperform by Oppenheimer
Immunovant Is Maintained at Outperform by Oppenheimer
Express News | Immunovant Inc : Oppenheimer Cuts Target Price to $46 From $50
Express News | Immunovant Inc : Guggenheim Cuts Target Price to $48 From $50
Immunovant (IMVT) Gets a Buy From Wells Fargo